Current Bare-Metal Stents: Similar to DES in the Very Long-Term

The largest randomized trial in history found no difference in the primary endpoint of death and nonfatal infarction between current conventional stents and drug-eluting stents at over 5 years in patients with stable or unstable coronary disease. As expected, NORSTENT did find a difference in revascularization rates between both groups.

 

This study presented at the European Society of Cardiology Congress was published simultaneously in the New England Journal of Medicine (NEJM) and randomized 9013 patients with stable or unstable coronary disease to undergo an angioplasty receiving either a contemporary drug-eluting stent (DES) or a contemporary conventional bare metal stent (BMS). Notably, 95% of the DES used were everolimus- or zotarolimus-eluting stents. Dual antiplatelet therapy was used for at least 9 months in both trial arms.

 

After 6 years of follow-up, primary endpoint events occurred as follows:

  • In 16.6% of patients receiving DES.
  • In 17.1% of patients receiving BMS

(p = 0.66).

 

No differences were observed after separately comparing the components of the primary outcome.

 

Unsurprisingly, repeat revascularization was more frequent in the BMS group (19.8% vs. 16.5%; p < 0.001). Definite thrombosis tended to be more frequent in the BMS group compared to the DES group (1.2% vs. 0.8%, respectively; p = 0.0498).

 

Original title: Drug-eluting or bare-metal stents for coronary artery disease.

Presenter: Kaare Harald Bonaa.

bare_metal

 

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Andexanet Alfa: a Good Antidote against Anti Xa Agents

Andexanet alfa induces rapid reversion of Xa inhibitor effect in patients with active major bleeding, according to preliminary observations of the ongoing study ANNEXA-4,...

DES: Best Option in Saphenous Vein Grafts

These results confirm that, despite being used less and less worldwide, DES (drug eluting stents) are the best option in saphenous vein grafts.   Saphenous vein...

OCT Improves Outcomes in Non ST Elevation ACS

This study presented at the ESC and simultaneously published in Circulation, is the first randomized controlled study to support the use of optical coherence...

Patients with Plaque Erosion: Management without Stenting

This small study presented at ESC and simultaneously published in the European Heart Journal evaluated patients undergoing acute coronary syndrome caused by plaque erosion identified by...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...